We serve Methyl L-threoninate hydrochloride CAS:39994-75-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name: Methyl L-threoninate hydrochloride
CAS.NO: 39994-75-7
Molecular Formula:C5H12ClNO3
Molecular Weight: 169.60700
Synonyms:
methyl (2S,3R)-2-amino-3-hydroxybutanoate,hydrochloride
L-Threonine methyl ester hydrochloride
Physical and Chemical Properties:
Density: /
Boiling point: 274.4ºC at 760 mmHg
Melting point: 64 °C
Flash point:119.8ºC
Refractive index: /
Specification:
Appearance:
Purity:≥98%
Loss on drying:≤0.20%
Residue on ignition[sulfated]:≤0.10%
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:-20ºC. Keep the container tightly closed, put it in a tight dispenser, and store in a cool, dry place.
Application:L-Threonine methyl ester is a protected form of L-Threonine. L-Threonine is an essential amino acid that is commonly used as a feed and food additive. L-Threonine is produced in mass quantities by mutant Escherichia coli strains for research and food nutrition purposes. L-Threonine can be naturally found in fish and poultry, and is incorporated in some important proteins in the human body (such as hemoglobin and insulin).
Contact us for information like Methyl L-threoninate hydrochloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,L-Threonine methyl ester hydrochloride physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,L-Threonine methyl ester hydrochloride Use and application,L-Threonine methyl ester hydrochloride technical grade,usp/ep/jp grade.
Related News: Zhejiang Huahai Pharmaceutical: It is a leading company in domestic APIs, especially in the field of cardiovascular drugs.4-nitrophenol manufacturer In recent years, the government has heavily promoted TCM, as part of efforts by Xi to bolster the country’s health sector and fill the gaps in national insurance schemes.Ethyl Cyclopropanecarboxylate supplier This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?(2-methyl-5-nitrophenyl) nitrate vendor This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?
